ASCO 2026 Abstracts

Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Defining APOBEC-like signature in diffuse large B-cell lymphoma and demonstration of distinct transcriptomic profile.

Presenter: Adam Albitar, MD

Date: Jun 1, 2026 – – 9 AM – 12PM CDT

Abstract: 7075 Poster Board 573

Session Breast Cancer—Metastatic

Dominant chromosomal abnormalities in breast cancer metastasis to CNS as compared with systemic metastasis demonstrated by liquid biopsy.

Presenter: To Be Determined

Date: Jun 1, 2026 – 1:30-4:30 PM CDT

Abstract: 1035 Poster Board 149

Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Distinction of FLT3-ITD transcriptomic signature from FLT3-TKD and the frequency of this signature in acute myeloid leukemia without FLT3 mutation.

Presenter: Maher Albitar

Date: Jun 1, 2026 – 9 AM – 12PM CDT

Abstract: 6538 Poster board 331

Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Comprehensive profiling and clinical utility of CSF-derived cell-free DNA/RNA for evaluation of solid and hematologic malignancies affecting the central nervous system.

Presenter: Renee Morecroft, MBBS

Date: May 30, 2026

Abstract: 3066 Poster Board203

Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

TP53 mutation adoption of stromal-adhesion/neuronal-like programs as a driver of stress adaptation and acute myelogenous leukemia cell survival.

Presenter: Alexandra Thalberg, BS

Date: Jun 1, 2026

Abstract:6545 Poster Board: 338

Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

A two-axis machine learning framework for cell-of-origin inference in AML: A proof-of-concept study.

Presenter: Alexandra Thalberg, BS

Date: Jun 1, 2026

Abstract: 6540 Poster Board: 333